Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-03-01

Clinical Trial Update: Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of pembrolizumab in advanced Merkel cell carcinoma completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Merkel Cell Carcinoma, Stage III Merkel Cell Carcinoma AJCC v7 | Phase 2 | Status: COMPLETED | Results posted: 2019-03-01